解剖学报 ›› 2019, Vol. 50 ›› Issue (6): 754-760.doi: 10.16098/j.issn.0529-1356.2019.06.009

• 肿瘤生物学 • 上一篇    下一篇

西达本胺增加慢性髓系白血病耐药株K562/ADM细胞对柔红霉素的敏感性

王世广1 司旭艳2 李晓婷1 李登云1 王丽君1 王鹏3*   

  1. 1.郑州工业应用技术学院医学院医学机能教研室,河南 新郑 451150; 2.郑州工业应用技术学院临床基础教研室,河南 新郑 451150; 3.郑州大学护理学院基础教研室, 郑州 450052
  • 收稿日期:2018-10-29 修回日期:2019-05-22 出版日期:2019-12-06 发布日期:2019-12-06
  • 通讯作者: 王鹏 E-mail:upliz@zzu.edu.cn
  • 基金资助:
    国家自然科学基金资助项目;河南省高等学校重点科研项目;河南省高等学校重点科研项目;河南省卫生与计划生育委员会医学教育研究课题

Enhancing effect of chidamide on the sensibility of human chronic myeloid leukemia K562/ADM cells to daunorubicin

WANG Shi-guang1 SI Xu-yan2 LI Xiao-ting1 LI Deng-yun1 WANG Li-jun1 WANG Peng 3*   

  1. 1.Department of Medical Function, Medical College, Zhengzhou University of Industrial Technology, He’nan Xinzheng 451150, China; 2.Department of Clinical Foundation, Medical College, Zhengzhou University of Industrial Technology, He’nan Xinzheng 451150, China; 3.Department of Basic, College of Nursing, Zhengzhou University, Zhengzhou 450052, China
  • Received:2018-10-29 Revised:2019-05-22 Online:2019-12-06 Published:2019-12-06
  • Contact: WANG Peng E-mail:upliz@zzu.edu.cn

摘要:

目的 观察西达本胺(CDM)能否影响人慢性髓系白血病耐药株K562/ADM细胞对柔红霉素(DNR)的敏感性,并探讨其可能的分子机制。方法 体外常规培养K562细胞和K562/ADM细胞,给予不同剂量CDM和(或)DNR处理48 h后,采用细胞计数试剂盒8(CCK-8)法检测CDM与DNR对K562和K562/ADM细胞的毒性作用,采用Chou-Talalay中效分析法对两药的联合效应进行评价,采用流式细胞术检测细胞增殖、细胞周期和凋亡,采用Western blotting方法检测组蛋白2AX(H2AX)、γH2AX(Ser139)、共济失调毛细血管扩张征突变基因(ATM)、p-ATM(Ser1981)、乳腺癌易感蛋白l(BRCA1)和p-BRCA1(Ser1524)的蛋白表达水平。 结果 DNR可剂量依赖性地抑制K562/ADM细胞活力(P<0.05),半数抑制浓度(IC50)为11.76 μmol/L,耐药倍数为18.09;CDM可协同增强DNR对K562/ADM细胞的抑制作用置信区间(CI)(CI<1),反转倍数为8.11;与对照组相比,DNR组细胞增殖率显著降低(P<0.05),G2/M期细胞比例和凋亡率明显升高(P<0.05),而无毒剂量的CDM可协同增强DNR引起的细胞增殖抑制、G2/M期阻滞和细胞凋亡(P<0.05);耐药株K562/ADM细胞中ATM和BRCA1蛋白表达水平显著高于其亲代K562细胞(P<0.05);DNR可上调K562/ADM细胞中H2AX、ATM和BRCA1蛋白的磷酸化水平(P<0.05);CDM与DNR联用可使γH2AX蛋白水平进一步升高,但p-ATM和pBRCA1蛋白水平的变化则相反(P<0.05)。 结论 CMD可反转K562/ADM细胞对DNR的耐药性,这可能与上调H2AX蛋白的磷酸化水平以及下调ATM和BRCA1蛋白的磷酸化水平有关。

关键词: 西达本胺, 柔红霉素, K562/ADM细胞, 乳腺癌易感蛋白l, 组蛋白2AX, 流式细胞术,

Abstract:

Objective To investigate whether chidamide (CDM) could influence the sensibility of human chronic myeloid leukemia K562/ADM cells to daunorubicin (DNR) and its possible mechanism. Methods The K562 and K562/ADM cells were cultured in vitro and treated with CDM and(or) DNR for 48 hous, and then the cell viability was measured by cell counting kit-8(CCK-8) assay. The proliferation, cell cycle and apoptosis were analyzed by flow cytometry. Western blotting was performed to measure the protein levels of histon 2AX(H2AX), γH2AX (Ser139), ataxia telangiectasia mutated gene (ATM), p-ATM (Ser1981), breast cancer susceptibility protein 1(BRCA1), and p-BRCA1 (Ser1524). Results DNR remarkably inhibited the cell activity of K562/ADM cells in dose-dependent manner with a half maximal inhibitory concentration(IC50) value of 11.76 μmol/L, and the resistant factor was 18.09. Co-treatment with CMD and DNR produced a synergistic effect confidence interval(Cl)(CI<1) with a reversal fold of 8.11. DNR remarkably inhibited proliferation (P<0.05), induced G2/M phase arrest and apoptosis (P<0.05), these effects were enhanced under non-toxic concentration of CMD (P<0.05). K562/ADM cells had a significantly higher protein levels of ATM and BRCA1 than K562 cells (P<0.05). DNR significantly up-regulated the protein levels of γH2AX, p-ATM and p-BRCA1 (P<0.05), and the protein level of γH2AX appeared higher in the combination group compared to DNR alone (P<0.05); however, the co-treatment with CMD and DNR induced a decreased expression of p-ATM and pBRCA1 than the DNR alone (P<0.05). Conclusion CDM may enhance the sensibility of K562/ADM cells to DNR by up-regulating the protein level of γH2AX, and down-regulating the protein levels of p-ATM and p-BRCA1.

Key words: Chidamide, Daunorubicin, K562/ADM cell, Breast cancer susceptibility protein 1, Histon2AX, Flow cytomertry, Human